Daily Respiratory Research Analysis
Analyzed 89 papers and selected 3 impactful papers.
Summary
Three impactful respiratory studies stood out today: a large randomized trial found no disease-free survival benefit with adjuvant durvalumab after complete resection of early-stage NSCLC, a multicenter cohort showed RSV carries the highest 30-day mortality among older adults hospitalized with acute respiratory symptoms, and a cross-sectional study introduced a digital respiratory effort metric (REMOV) that aligns more closely with patient-reported outcomes than AHI in obstructive sleep apnea.
Research Themes
- Perioperative immunotherapy in lung cancer
- RSV severity and outcomes in older adults
- Digital phenotyping for obstructive sleep apnea
Selected Articles
1. Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.
In the BR.31 randomized trial of 1,415 patients with completely resected stage IB (≥4 cm)–IIIA NSCLC, adjuvant durvalumab given every 4 weeks for 12 cycles did not improve investigator-assessed disease-free survival compared with placebo, including in the prespecified PD-L1 tumor cell ≥25% subgroup. Randomization was stratified by stage, nodal dissection, PD-L1, adjuvant chemotherapy, and center.
Impact: This large, stratified RCT provides definitive negative evidence against routine adjuvant durvalumab after resection, informing perioperative immunotherapy strategies in early-stage NSCLC.
Clinical Implications: Adjuvant durvalumab should not be routinely offered after complete resection of early-stage NSCLC outside clinical trials; clinicians should consider alternative perioperative regimens and ongoing neoadjuvant/adjuvant trial evidence when tailoring care.
Key Findings
- Randomized 1,415 patients with resected stage IB (≥4 cm) to IIIA NSCLC 2:1 to durvalumab 20 mg/kg or placebo every 4 weeks for 12 cycles.
- Primary endpoint was investigator-assessed disease-free survival; durvalumab did not improve DFS versus placebo.
- Primary analysis focused on PD-L1 tumor cell ≥25% subgroup; stratification included stage, nodal dissection extent, PD-L1, adjuvant chemotherapy, and center.
Methodological Strengths
- Large, multicenter, placebo-controlled randomized design with prespecified stratification.
- Clear primary endpoint (disease-free survival) and predefined PD-L1 subgroup analysis.
Limitations
- Optional adjuvant chemotherapy may introduce treatment heterogeneity across arms.
- Investigator-assessed DFS and lack of detailed OS results in the abstract limit interpretability.
Future Directions: Clarify perioperative strategies by evaluating neoadjuvant immunotherapy, combination regimens, and alternative biomarkers beyond PD-L1 to select patients most likely to benefit.
PURPOSE: Adjuvant immunotherapy improved patient outcomes in two trials in completely resected non-small cell lung cancer (NSCLC), but with conflicting primary end point results. The Canadian Cancer Trials Group BR.31 trial evaluated adjuvant durvalumab in completely resected early-stage NSCLC. METHODS: Following resection of stage IB (≥4 cm) to IIIA NSCLC (American Joint Committee on Cancer 7th Edition) and optional adjuvant chemotherapy, patients were randomly assigned 2:1 to durvalumab 20 mg/kg or placebo 20 mg/kg once every 4 weeks for 12 cycles. Random assignment was stratified by stage, extent of nodal dissection, tumor cell (TC) PD-L1 expression, adjuvant chemotherapy use, and center. The primary end point was investigator-assessed disease-free survival (DFS). Secondary outcomes included overall survival (OS), adverse events, and quality of life. The primary analysis was in the subgroup with cancers that had a PD-L1 TC expression ≥25%, no common activating RESULTS: Of 1,415 patients randomly assigned, 1,219 (86%) had CONCLUSION: Adjuvant durvalumab following complete resection was not associated with improvement in DFS compared with placebo in
2. Prevalence and clinical outcomes of RSV, COVID-19, and influenza among older hospitalized adults: The EVERY prospective cohort study.
In 3,067 adults aged ≥50 emergently hospitalized with acute respiratory symptoms, RSV prevalence was 1.6% but conferred the highest 30-day mortality (14.3%) versus COVID-19 (8.4%) and influenza (2.9%). Lower respiratory tract infection rates were high across viruses, and adjusted analyses indicated markedly higher odds of death with RSV compared with influenza.
Impact: This prospective multicenter cohort quantifies RSV’s disproportionate lethality among older inpatients with acute respiratory illness, strengthening the case for targeted prevention, vaccination uptake, and triage prioritization.
Clinical Implications: Clinicians should maintain high suspicion for RSV in older adults with acute respiratory illness, escalate supportive care and monitoring, and promote RSV vaccination; hospitals may consider RSV-season surge planning and rapid diagnostics to guide isolation and treatment.
Key Findings
- Among 3,067 adults ≥50 years, virus prevalences were: RSV 1.6%, COVID-19 18.0%, Influenza A/B 2.3%.
- 30-day mortality was highest with RSV (14.3%) versus COVID-19 (8.4%) and Influenza (2.9%); adjusted odds of death were higher for RSV vs influenza.
- Lower respiratory tract infection rates were high across viruses (e.g., RSV 87.8%; influenza 88.4%).
Methodological Strengths
- Prospective multicenter design with standardized multiplex molecular testing.
- Adjusted analyses for mortality and clearly defined clinical endpoints including 30-day mortality.
Limitations
- RSV vaccination rate was 0% during the study period, limiting assessment of vaccine effectiveness.
- RSV prevalence was low, which may affect precision of subgroup analyses.
Future Directions: Evaluate the impact of RSV vaccination and antivirals on hospitalization outcomes, develop risk stratification tools for early escalation, and assess health system surge planning during RSV seasons.
OBJECTIVES: The impact of respiratory syncytial virus (RSV) among older adults hospitalized for acute respiratory symptoms was uncertain. We compared the prevalence and clinical outcomes of RSV with those of coronavirus disease 2019 (COVID-19) and influenza in older adults hospitalized for acute respiratory symptoms. METHODS: We conducted a multicenter prospective cohort study at 3 community hospitals, which enrolled emergently hospitalized adults aged ≥50 years with acute respiratory symptoms or signs from July 1, 2023, to December 31, 2024. RSV, COVID-19, and Influenza A/B were measured with FilmArray Respiratory 2.1 panel on nasopharyngeal swab. The primary outcomes were lower respiratory tract infections (LRTIs), defined as presence of ≥2 lower respiratory symptoms/signs for at least 24 hours including ≥1 lower respiratory sign, or presence of ≥3 lower respiratory symptoms for at least 24 hours; modified LRTIs, incorporating chest radiography or computed tomography; and the 30-day all-cause mortality. RESULTS: During the 18-month study period, 3067 patients were included, with a mean age of 81 years (SD 11) and 55% of whom were male. Comorbidities included chronic pulmonary diseases (28%), chronic heart failure (32%), and diabetes (30%). The vaccination rates for RSV, COVID-19, and influenza were 0%, 62.3%, and 37.9%, respectively. The prevalences of RSV, COVID-19, and Influenza A/B were 1.6%, 18.0%, and 2.3%, respectively. The rates of LRTIs were 87.8% (RSV), 82.8% (COVID-19), and 88.4% (Influenza A/B). The rates of modified LRTIs were exhibited a marginal increase. The 30-day mortality was highest among patients with RSV (14.3%) compared to those with COVID-19 (8.4%), and Influenza A/B (2.9%) (P < .0001). The adjusted ORs (95%CI) of 30-day mortality with RSV and COVID-19 relative to Influenza A/B were 5.2 (1.2-36.7) and 2.9 (0.83-17.9), respectively. CONCLUSIONS: RSV should be recognized as a risk factor for mortality among older adults emergently hospitalized for acute respiratory symptoms.
3. Respiratory effort burden measured by mandibular jaw movements as a digital marker with clinical insights in obstructive sleep apnea.
In 1,000 adults referred for suspected OSA, a mandibular jaw movement–derived metric (REMOV) tracked respiratory effort burden and correlated with sleepiness, fatigue, and depression, particularly in those with AHI ≤15 events/h. AHI showed no significant association with patient-reported outcomes, suggesting REMOV may complement AHI for severity grading and treatment decisions.
Impact: By linking a noninvasive digital effort metric to meaningful symptoms, this study challenges AHI-centric assessment and could shift OSA phenotyping toward physiology- and patient-centered metrics.
Clinical Implications: Incorporating REMOV into OSA evaluation could better identify symptomatic patients—especially with mild AHI—who may benefit from earlier interventions. It supports tailored therapy beyond AHI thresholds.
Key Findings
- REMOV increased with OSA severity categories and was significantly associated with sleepiness, fatigue, and depression, most strongly when AHI ≤15 events/h.
- AHI did not significantly correlate with patient-reported outcomes, highlighting a disconnect between event counts and clinical burden.
- Study used simultaneous polysomnography, mandibular jaw movement analysis, and validated questionnaires in 1,000 adults.
Methodological Strengths
- Large sample with concurrent polysomnography and automated effort analysis.
- Use of validated patient-reported outcomes and multivariate analyses.
Limitations
- Cross-sectional design limits causal inference and prognostic validation.
- Generalizability may be restricted to referred populations and specific device algorithms.
Future Directions: Prospective studies should test REMOV-guided treatment strategies, validate thresholds for intervention, and assess longitudinal outcomes and adherence impacts.
BACKGROUND: The clinical symptoms of obstructive sleep apnea (OSA) are poorly correlated with disease severity based on the apnea-hypopnea index (AHI). The cumulative duration of respiratory effort assessed by mandibular jaw movement monitoring with automated analysis (REMOV) may better capture the clinical burden of OSA. This cross-sectional study assessed the association between REMOV and patient-reported outcomes (PROs), including sleepiness, fatigue, and depression. METHODS: One thousand adults referred for suspected OSA underwent polysomnography, REMOV analysis, and PRO assessment using validated questionnaires. Relationships between REMOV, AHI, and PROs were examined using principal component analysis and regression models. RESULTS: Median REMOV values align with OSA severity (6.5%, 23.4%, 28.8%, and 42.8% of total sleep time at AHI values of <5, 5-15, 15- < 30, and ≥30 events/h, respectively). REMOV is significantly associated with sleepiness, fatigue, and depression. These associations are most evident in patients with an AHI ≤ 15 events/h. AHI is not significantly associated with any PROs. CONCLUSIONS: These data suggest that REMOV may serve as a complementary metric in OSA, especially in patients with mild disease. Incorporating REMOV into OSA severity grading may improve the alignment between PROs and therapeutic decisions. Obstructive sleep apnea (OSA) can cause excessive daytime sleepiness, fatigue, or depressed mood. However, these symptoms often do not align with the conventional apnea-hypopnea index (AHI), which measures the number of breathing interruptions per hour of sleep. This study tested a new metric called REMOV, which quantifies the percentage of sleep time spent with increased respiratory effort. We studied 1,000 adults referred for suspected OSA. Each participant underwent an overnight polysomnography with simultaneous REMOV measurement based on mandibular jaw movement analysis and completed questionnaires about their symptoms. We found that higher REMOV values were significantly associated with more severe symptoms, especially in patients with mild OSA. Our findings suggest that REMOV could complement the AHI in routine practice, supporting earlier treatment decisions, and thereby improving OSA management outcomes.